



Figure S1 Proportion of common pathogens in each year

Table S1 Differences of antibiotic susceptibility of *Escherichia coli* in late-onset infection between the two epochs

| | First epoch (2009–2014), (N=20), n/N (%) | Second epoch (2015–2020), (N=21), n/N (%) | P value |
|-------------------------|--|---|---------|
| Ampicillin/Sulbactam | 6/20 (30.0) | 8/19 (42.1) | 0.431 |
| Piperacillin/Tazobactam | 19/20 (95.0) | 19/19 (100.0) | 1.000* |
| Gentamicin | 12/20 (60.0) | 12/18 (66.7) | 0.671 |
| Ciprofloxacin | 14/20 (70.0) | 11/19 (57.9) | 0.431 |
| Cefuroxime | 7/20 (35.0) | 14/18 (77.8) | 0.008 |
| Cefotaxime | 7/20 (35.0) | 12/13 (92.3) | 0.001 |
| Ceftazidime | 10/20 (50.0) | 17/19 (89.5) | 0.008 |
| Cefoperazone/Sulbactam | 17/20 (85.0) | 19/19 (100.0) | 0.231* |
| Cefepime | 16/20 (80.0) | 20/21 (95.2) | 0.184* |

* Fisher's exact test for Piperacillin/Tazobactam, Cefoperazone/Sulbactam, Cefepime.